Last reviewed · How we verify
Sensoril
Sensoril is a Small molecule drug developed by University of Pittsburgh. It is currently in Phase 3 development. Also known as: Ashwagandha, Withania somnifera.
Sensoril, a dietary supplement containing an aqueous extract of roots plus leaves of Withania somnifera, has been studied in clinical trials for its potential effects on elevated S-adenosylhomocysteine, immune health, hair thinning, and bipolar disorders. The exact mechanism of Sensoril is not specified in the provided information, but it has been tested in combination with other interventions such as Alpha-GPC and Creatine in clinical trials.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Sensoril |
|---|---|
| Also known as | Ashwagandha, Withania somnifera |
| Sponsor | University of Pittsburgh |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 3 |
Approved indications
Common side effects
Key clinical trials
- Efficacy and Safety of a Nutraceutical Supplement With Standardized Botanicals in Peri-menopausal and Menopausal Women With Thinning Hair (NA)
- Adjunctive Withania Somnifera (Ashwagandha) for Persistent Symptoms in People With Schizophrenia (PHASE2, PHASE3)
- Role of a Dietary Supplement in Lowering SAH in Healthy Adults With Elevated Plasma SAH and Normal Homocysteine Levels (NA)
- Nutraceutical Supplement With Standardized Botanicals in Males With Thinning Hair (NA)
- Nutraceutical Supplement With Vegan Botanicals in Females With Self-Perceived Thinning Hair (NA)
- Efficacy and Tolerability of Sensoril® in Improving Immunity and Thereby Reducing Incidence of Upper Respiratory Tract Infections (NA)
- Efficacy and Safety of a Nutraceutical Supplement With Standardized Botanicals in Women With Thinning Hair (NA)
- Withania Somnifera: an Immunomodulator and Anti-inflammatory Agent for Schizophrenia (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sensoril CI brief — competitive landscape report
- Sensoril updates RSS · CI watch RSS
- University of Pittsburgh portfolio CI
Frequently asked questions about Sensoril
What is Sensoril?
Who makes Sensoril?
Is Sensoril also known as anything else?
What development phase is Sensoril in?
Related
- Manufacturer: University of Pittsburgh — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: Ashwagandha, Withania somnifera
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing